Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 13;8(1):e08747.
doi: 10.1016/j.heliyon.2022.e08747. eCollection 2022 Jan.

Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial

Affiliations

Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial

Stanislav Pekarskiy et al. Heliyon. .

Abstract

Background: Historical reports on surgical renal denervation consistently describe renal plexus as a triangle or fan-like structure converging at the kidney gate. Following that anatomy, we developed a distal mode of radiofrequency renal denervation (RDN) mainly in segmental branches of the renal artery and confirmed its superior efficacy over the conventional main trunk procedure in a 6-months double-blind randomized controlled trial (NCT02667912). To assess the long-term effects of distal RDN we extended the follow-up of our study to three years.

Methods: BP, serum creatinine, eGFR were measured one and three years after randomization; major adverse renal events were assessed over the entire study period. The blinding was maintained over the entire three-year study period.

Findings: Of 55 randomized patients, 47 (23/24, distal/main trunk RDN, respectively) were assessed at one year and 39 (21/18) at three years post-procedure. Twenty-four-hour ambulatory systolic BP remained powerfully lowered after distal RDN both at one- and three-years assessments(mean change from baseline: -18.0, 95% CI -27.6 to -8.5; p<0.05 and -16·9, 95% CI -27·3 to -6·5; p<0·05, mmHg, respectively. This was accompanied by a moderate drop in eGFR at one year: -8·9 ml/min/m2, 95% CI -14·8 to -3·1; p<0·05, which, however, subsequently decreased in size at three years: -6·5, 95% CI -13·2 to 0·3; p>0·05. After main trunk RDN, the decrease of 24h systolic BP was quite moderate at one year: -12·1, 95% CI -19·2 to -5·0; p<0·05, and further weakened at three-year assessment: -8·5, 95% CI -19·7 to 2·2; p>0.05. eGFR was almost unchanged at one year: -1·3, 95% CI -6·6 to 4·0; p>0·05, but significantly decreased at three years: -5·0, 95% CI -9·6 to -0·3; p<0·05.

Interpretation: Our data demonstrate the durable strong BP-lowering efficacy and favorable long-term renal safety of distal RDN.

Keywords: Ambulatory; Arterial catheterization; Blood pressure monitoring; Essential hypertension; Peripheral; Radiofrequency ablation; Renal artery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A. Actual anatomy of the renal nerve plexus. B. Anatomically optimized distal renal denervation.
Figure 2
Figure 2
Study flow chart.
Figure 3
Figure 3
The decrease in office and ambulatory systolic BP at 6, 12, and 36 months after distal and conventional RDN compared to baseline. A. The decrease in twenty-four-hour mean systolic BP. B. The decrease in daytime mean systolic BP. C. The decrease in nighttime mean systolic BP. D. The decrease in office systolic BP. ∗ - p < 0.05; sys BP - systolic blood pressure.

References

    1. Heart disease and stroke statistics—2017 update. A report from the American Heart Association. Circulation. 2017;135:e146–e603. - PMC - PubMed
    1. Judd E., Calhoun D.A. Apparent and true resistant hypertension: definition, prevalence and outcomes. J. Hum. Hypertens. 2014 Aug;28(8):463–468. Epub 2014 Jan 16. PMID: 24430707; PMCID: PMC4090282. - PMC - PubMed
    1. Cramer J.A., Benedict A., Muszbek N., Keskinalsan A., Khan Z.M. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 2008;62:76–87. - PMC - PubMed
    1. Morrissey D.M., Brookes VictorS., Cooke W.T. Sympathectomy in the treatment of hypertension review of 122 cases. Lancet. 1953;261(6757) https://www.sciencedirect.com/science/article/pii/S014067365391589X 403-408, ISSN 0140-6736. - PubMed
    1. Smithwick R.H., Thompson J.E. Splanchnicectomy for essential hypertension: results in 1,266 cases. JAMA. 1953;152(16):1501–1504. - PubMed